To Evaluate OBI-833/OBI-821 in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer for Recurrence

Esophageal Cancer Clinical Trial

Official title:

A Randomized, Open-Label, Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT05376423
• Other study ID #: 202106018MIPB
• Status: Recruiting
• Phase: Phase 2
• Start date: June 2, 2022
• Est. completion date: June 2025

Study information

• Verified date: November 2023
• Source: National Taiwan University Hospital
• Contact: Jang-Ming Lee
• Phone: +886-2-23123456
• Email: jangminglee[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 2 Study to Evaluate Adjuvant OBI-833/OBI-821 Therapy in Patients With Locally Advanced, Globo H-Positive Esophageal Cancer at High Risk for Recurrence

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 60
• Est. completion date: June 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Inclusion Criteria:

1. Male or female patients, 20 years of age or older at the time of consent.

2. Pathologically or cytologically confirmed diagnosis of esophageal cancer (including squamous cell carcinoma and adenocarcinoma) whose postneoadjuvant pathologic stage is ypT1-4 AND ypN1-3 according to the AJCC Cancer Staging System, 8th Edition.

3. Patients have been treated with preoperative cisplatin-based chemoradiotherapy followed by esophagectomy with lymph node dissection for locally advanced esophageal cancer (defined by the above criterion).

4. Postneoadjuvant pathologic staging: ypT1-4 and ypN1-3.

5. Globo H IHC H-score =1 in the surgical tumor specimen from the primary site/or lymph node (if the primary site is not available). The Globo H expression will be determined by a qualified laboratory.

6. R0 (no residual tumor on the surgical margin of the resected tumor specimen).

7. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.

8. Organ Function Requirements - Subjects must have adequate organ functions as defined below:

• AST/ALT = 3X ULN (upper limit of normal)

• Total bilirubin = 2X ULN

• Serum creatinine = 1.5X ULN

• ANC ? 1,500 /µL

• Platelets ? 100,000/µL

9. All eligible patients of childbearing potential must use effective contraception during study treatment and for at least 2 months after the last dose of OBI-833/OBI-821. Subjects not of childbearing potential (i.e., permanently sterilized, postmenopausal) can be included in the study. Postmenopausal is defined as 12 months with no menses without an alternative medical cause.

10. Ability to understand and the willingness to sign a written informed consent document according to institutional guidelines.

Exclusion Criteria:

1. Subjects who cannot be randomized within 8 weeks after the esophageal cancer surgery.

2. Subjects who are pregnant or breast-feeding at entry.

3. Subjects with splenectomy.

4. Has prior malignancy, except (a) adequately treated basal cell or squamous cell skin cancer; (b) in situ cervical cancer; (c) previously diagnosed malignancy which has been adequately treated and shown no evidence of recurrence for more than 5 years.

5. Subjects with HIV infection, active hepatitis B infection, or active hepatitis C infection.

6. Subjects with any autoimmune or other disorders requiring IV/oral steroids or immunosuppressive or immunomodulatory therapies.

• e.g., type 1 juvenile-onset diabetes mellitus, antibody positive for rheumatoid arthritis, Graves disease, Hashimoto thyroiditis, lupus, scleroderma, systemic vasculitis, hemolytic anemia, immune mediated thrombocytopenia, Crohn disease, ulcerative colitis, and psoriasis.

7. Subjects with any known uncontrolled comorbid illness, including ongoing or active infections, symptomatic congestive heart failure (NYHA>2), unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

8. Subjects who have received any of the following medications within 4 weeks prior to randomization:

• Immunotherapy, including monoclonal antibodies, cytokines, interferons, and checkpoint inhibitors.

• Immunosuppressants, including cyclosporin, rapamycin, tacrolimus, rituximab, alemtuzumab, natalizumab, and cyclophosphamide.

• Other biologics, including G-CSF and other hematopoietic growth factors.

• Live attenuated vaccines.

• IV/oral steroids except single prophylactic use in CT/MRI scan or other one-time use in approved indications. Use of inhaled and topical (except on the injection site) steroids is allowed.

• Alternative and complementary medicine that may affect the immune system.

• Other investigational drugs

9. Unresolved toxicities from prior anticancer therapy, defined as having not resolved to Grade 0 or 1 (using National Cancer Institute Common Terminology Criteria for Adverse Events [NCI CTCAE] version 5.0), except for alopecia and laboratory values listed in the inclusion criteria.

10. Subjects with any known severe allergies (e.g., anaphylaxis) to any active or inactive ingredients in the study drugs.

11. Any other reason that the investigator deems the patient as unsuitable for the study.

Related Conditions & MeSH terms

• Esophageal Cancer
• Esophageal Neoplasms
• Recurrence

Intervention

Biological:
• OBI-833/OBI-821
OBI-833 and OBI-821 are individually formulated into separate glass vials. The articles are mixed prior to subcutaneous administration at the clinic.

Locations

Country	Name	City	State
Taiwan	National Taiwan University Hospital	Taipei

Sponsors (1)

Lead Sponsor	Collaborator
National Taiwan University Hospital

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Recurrence-free survival rate	To evaluate the effect of OBI-833/OBI-821 treatment on improving recurrence-free survival in patients with locally advanced, Globo H-positive esophageal cancer in the adjuvant setting	one year